Are you Dr. Balk?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-5288
Summary
- Dr. Steven Balk, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is a Professor of Medicine at Beth Israel Deaconess Medical Center.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
Harvard Medical SchoolClass of 1983
Certifications & Licensure
MA State Medical License 1985 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1996
Clinical Trials
- In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer Start of enrollment: 2008 Feb 01
- Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer Start of enrollment: 2005 Feb 01
Publications & Presentations
PubMed
- Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.Larysa Poluben, Mannan Nouri, Jiaqian Liang, Shaoyong Chen, Andreas Varkaris
Cell Reports. 2024-12-21 - Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.Razia Rahman, Muhammed H Rahaman, Adrienne R Hanson, Nicholas Choo, Jianling Xie
British Journal of Cancer. 2024-11-01 - 1 citationsAKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L Dalrymple, Christopher M Dennehy
Molecular Cancer Therapeutics. 2024-10-01
Press Mentions
Thank You for Your PatientsMarch 23rd, 2020
The Prostate Cancer Foundation Awards $5.5 Million to PCF Challenge Award Recipients to Advance Prostate Cancer ResearchOctober 30th, 2018
Grant Support
- Training Grant In Cancer BiologyNational Cancer Institute2007–2011
- Targeting Ar-Ncor Interaction In Prostate CancerNational Cancer Institute2007–2011
- HTS For Androgen Receptor Antagonists That Recruit NcorNational Institute Of Neurological Disorders And Stroke2006
- AR Transgene Model Of Prostate Intraepithelial NeoplasiaNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2006
- Immune Regulation By CD1D Reactive NKR-P1 T CellsNational Institute Of Allergy And Infectious Diseases1999–2003
- Androgen Receptor In Hormone Refractory DiseaseNational Cancer Institute2002
- Invariant NKT Cells For Phase 1 Cancer TrialsNational Cancer Institute2001–2002
- Function Of Human Intestinal Intraepithelial LymphocytesNational Institute Of Allergy And Infectious Diseases1993–2001
- AR Mutations In Androgen-Independent Prostate CancerNational Cancer Institute1996–1999
- Immune Regulation By CD1D Reactive Nkp-P1 T CellsNational Institute Of Allergy And Infectious Diseases1998
- Isolation Of A Human Homologue Of The Murine LY-6 SystemNational Cancer Institute1989
- Isolation Of A Human Homologue Of The Murine LY-6 SystemNational Cancer Institute1987–1988
